Buti S.; Ciccarese C.; Iacovelli R.; Bersanelli M.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Montironi R.; Tortora G.; Massari F., Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 1 - Kidney cancer, «FUTURE ONCOLOGY», 2016, 12, pp. 1967 - 1970 [articolo]
Buti S.; Ciccarese C.; Iacovelli R.; Bersanelli M.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Montironi R.; Tortora G.; Massari F., Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 2 - Prostate and bladder cancer, «FUTURE ONCOLOGY», 2016, 12, pp. 1971 - 1974 [articolo]
Modena A.; Iacovelli R.; Scarpa A.; Brunelli M.; Ciccarese C.; Fantinel E.; Bimbatti D.; Massari F.; Martignoni G.; Tortora G., Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer, «TARGETED ONCOLOGY», 2016, 11, pp. 569 - 577 [articolo]
Ciccarese C.; Tortora G.; Montironi R.; Massari F., Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?, «TRANSLATIONAL CANCER RESEARCH», 2016, 5, pp. 1061 - 1065 [articolo]
Massari F.; Ciccarese C.; Calio A.; Munari E.; Cima L.; Porcaro A.B.; Novella G.; Artibani W.; Sava T.; Eccher A.; Ghimenton C.; Bertoldo F.; Scarpa A.; Sperandio N.; Porta C.; Bronte V.; Chilosi M.; Bogina G.; Zamboni G.; Tortora G.; Samaratunga H.; Martignoni G.; Brunelli M., Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis, «TARGETED ONCOLOGY», 2016, 11, pp. 345 - 351 [articolo]
Ciccarese C.; Santoni M.; Massari F.; Modena A.; Piva F.; Conti A.; Mazzucchelli R.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Tortora G.; Montironi R., Metabolic alterations in renal and prostate cancer, «CURRENT DRUG METABOLISM», 2016, 17, pp. 150 - 155 [articolo]
Massari F.; Ciccarese C.; Santoni M.; Iacovelli R.; Mazzucchelli R.; Piva F.; Scarpelli M.; Berardi R.; Tortora G.; Lopez-Beltran A.; Cheng L.; Montironi R., Metabolic phenotype of bladder cancer, «CANCER TREATMENT REVIEWS», 2016, 45, pp. 46 - 57 [articolo]
Santoni M.; Massari F., mTOR Pathway in Renal Cell Carcinoma, «Molecules to Medicine with mTOR. Translating Critical Pathways Into Novel Therapeutic Strategies», 2016, 1, pp. 417 - 428 [articolo]
Ciccarese C.; Alfieri S.; Santoni M.; Santini D.; Brunelli M.; Bergamini C.; Licitra L.; Montironi R.; Tortora G.; Massari F., New toxicity profile for novel immunotherapy agents: Focus on immune-checkpoint inhibitors, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2016, 12, pp. 57 - 74 [articolo]
Conteduca V.; Crabb S.J.; Jones R.J.; Caffo O.; Elliott T.; Scarpi E.; Fabbri P.; Derosa L.; Massari F.; Numico G.; Zarif S.; Hanna C.; Maines F.; Joyce H.; Lolli C.; De Giorgi U., Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer, «PLOS ONE», 2016, 11, Article number: e0158952, pp. 1 - 12 [articolo]
Minardi D.; Mazzucchelli R.; Scarpelli M.; Massari F.; Ciccarese C.; Lopez-Beltran A.; Cheng L.; Montironi R., Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3, «FUTURE ONCOLOGY», 2016, 12, pp. 1431 - 1433 [articolo]
Santini D.; Santoni M.; Conti A.; Procopio G.; Verzoni E.; Galli L.; di Lorenzo G.; De Giorgi U.; De Lisi D.; Nicodemo M.; Maruzzo M.; Massari F.; Buti S.; Altobelli E.; Biasco E.; Ricotta R.; Porta C.; Vincenzi B.; Papalia R.; Marchetti P.; Burattini L.; Berardi R.; Muto G.; Montironi R.; Cascinu S.; Tonini G., Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma, «ONCOTARGET», 2016, 7, pp. 33381 - 33390 [articolo]
Maines F.; Caffo O.; De Giorgi U.; Fratino L.; Lo Re G.; Zagonel V.; D'Angelo A.; Donini M.; Verderame F.; Ratta R.; Procopio G.; Campadelli E.; Massari F.; Gasparro D.; Ermacora P.; Messina C.; Giordano M.; Alesini D.; Basso U.; Fraccon A.P.; Vicario G.; Conteduca V.; Galligioni E., Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme, «CLINICAL GENITOURINARY CANCER», 2016, 14, pp. 48 - 55 [articolo]
Lolli C.; Caffo O.; Scarpi E.; Aieta M.; Conteduca V.; Maines F.; Bianchi E.; Massari F.; Veccia A.; Chiuri V.E.; Facchini G.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone, «FRONTIERS IN PHARMACOLOGY», 2016, 7, Article number: 376, pp. 1 - 7 [articolo]
Lolli C.; Basso U.; Derosa L.; Scarpi E.; Sava T.; Santoni M.; Crabb S.J.; Massari F.; Aieta M.; Conteduca V.; Maruzzo M.; La Russa F.; Wheater M.; Berardi R.; Galli L.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, «ONCOTARGET», 2016, 7, pp. 54564 - 54571 [articolo]
